Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Top Cited Papers
Open Access
- 1 August 2002
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 2 (2) , 117-125
- https://doi.org/10.1016/s1535-6108(02)00096-x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Interaction between ATM protein and c-Abl in response to DNA damageNature, 1997
- An Activating Mutation in the ATP Binding Site of the ABL Kinase DomainPublished by Elsevier ,1996
- SETOR: Hardware-lighted three-dimensional solid model representations of macromoleculesJournal of Molecular Graphics, 1993
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990